244 related articles for article (PubMed ID: 34775907)
1. The use of buprenorphine + naloxone sublingual tablet in the treatment of neonatal opioid withdrawal syndrome: Two case reports.
Ulu E; Kandeğer A; Meriç R
J Addict Dis; 2022; 40(3):432-438. PubMed ID: 34775907
[TBL] [Abstract][Full Text] [Related]
2. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
[TBL] [Abstract][Full Text] [Related]
3. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
Bhatia G; Sarkar S
Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
[TBL] [Abstract][Full Text] [Related]
4. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film.
Gunderson EW; Sumner M
J Addict Med; 2016; 10(2):124-30. PubMed ID: 26918662
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine/Naloxone (Zubsolv
Heo YA; Scott LJ
CNS Drugs; 2018 Sep; 32(9):875-882. PubMed ID: 30117074
[TBL] [Abstract][Full Text] [Related]
7. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
Coish R; Hardial J
J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
[TBL] [Abstract][Full Text] [Related]
8. High-dose buprenorphine for treatment of high potency opioid use disorder.
Danilewitz M; McLean M
Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
10. "Macrodosing" Sublingual Buprenorphine and Extended-release Buprenorphine in a Hospital Setting: 2 Case Reports.
Kahan M; Marion-Bellemare L; Samson J; Srivastava A
J Addict Med; 2023 Jul-Aug 01; 17(4):485-487. PubMed ID: 37579117
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine.
Chhabra N; Aks SE
Am J Emerg Med; 2020 Mar; 38(3):691.e3-691.e4. PubMed ID: 31753622
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder.
Kanervo MM; Tupola SJ; Nikkola EM; Rantakari KM; Kahila HK
Acta Obstet Gynecol Scand; 2023 Mar; 102(3):313-322. PubMed ID: 36562462
[TBL] [Abstract][Full Text] [Related]
14. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
[TBL] [Abstract][Full Text] [Related]
15. A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine-naloxone tablets.
Modak T; Sarkar S; Balhara YPS
J Opioid Manag; 2021; 17(7):141-152. PubMed ID: 34520035
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update.
Soyka M
Expert Opin Drug Deliv; 2015 Feb; 12(2):339-47. PubMed ID: 25156759
[TBL] [Abstract][Full Text] [Related]
19. Effects of buprenorphine/naloxone in opioid-dependent humans.
Stoller KB; Bigelow GE; Walsh SL; Strain EC
Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
[TBL] [Abstract][Full Text] [Related]
20. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
Sullivan JG; Webster L
Clin Ther; 2015 May; 37(5):1064-75. PubMed ID: 25823919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
